Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 29;16(5):998.
doi: 10.3390/cancers16050998.

Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)

Julia Chisholm #  1 , Henry Mandeville #  1 , Madeleine Adams  2 , Veronique Minard-Collin  3 , Timothy Rogers  4 , Anna Kelsey  5 , Janet Shipley  6 , Rick R van Rijn  7 , Isabelle de Vries  8 , Roelof van Ewijk  8 , Bart de Keizer  8 , Susanne A Gatz  9   10 , Michela Casanova  11 , Lisa Lyngsie Hjalgrim  12 , Charlotte Firth  10 , Keith Wheatley  10 , Pamela Kearns  10 , Wenyu Liu  10 , Amanda Kirkham  10 , Helen Rees  13 , Gianni Bisogno  14 , Ajla Wasti  6 , Sara Wakeling  15 , Delphine Heenen  16 , Deborah A Tweddle  17 , Johannes H M Merks #  8 , Meriel Jenney #  2
Affiliations

Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)

Julia Chisholm et al. Cancers (Basel). .

Erratum in

Abstract

The Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) clinical trial is an overarching, multinational study for children and adults with rhabdomyosarcoma (RMS). The trial, developed by the European Soft Tissue Sarcoma Study Group (EpSSG), incorporates multiple different research questions within a multistage design with a focus on (i) novel regimens for poor prognostic subgroups, (ii) optimal duration of maintenance chemotherapy, and (iii) optimal use of radiotherapy for local control and widespread metastatic disease. Additional sub-studies focusing on biological risk stratification, use of imaging modalities, including [18F]FDG PET-CT and diffusion-weighted MRI imaging (DWI) as prognostic markers, and impact of therapy on quality of life are described. This paper forms part of a Special Issue on rhabdomyosarcoma and outlines the study background, rationale for randomisations and sub-studies, design, and plans for utilisation and dissemination of results.

Keywords: EpSSG; FaR-RMS; chemotherapy; clinical trial; novel agents; radiotherapy; randomisation; rhabdomyosarcoma.

PubMed Disclaimer

Conflict of interest statement

JCC is supported by The Giant Pledge through the Royal Marsden Cancer Charity. This work represents independent research supported by the National Institute for Health Research (NIHR) Biomedical Research Centre at The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London and the NIHR Birmingham Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. SAG has/has had an advisory role for EMD Serono/MERCK KGaA, AMGEN, and GILEAD; signed a consultancy agreement with AstraZeneca and Schroedinger Therapeutics; and received research funding (institution) from AstraZeneca, GSK, and BAYER. MC has had advisory and invited speaker roles for Bayer. SW leads the charity, Alice’s Arc which is funding the biological studies. PC is a member of the Advisory Board for AstraZeneca. JHMM has consultancy agreements with Merck, GSK and BAYER. BAYER has provided funding to the University of Birmingham for the FaR-RMS study.

Figures

Figure 1
Figure 1
Trial schema for FaR-RMS clinical trial.
Figure 2
Figure 2
Schema for radiotherapy randomisations for local disease site. 1: Higher local failure rate (LFR) defined as unfavourable site of patient aged ≥18 years.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. FaR-RMS: An Overarching Study for Children and Adults with Frontline and Relapsed RhabdoMyoSarcoma—Full Text View—ClinicalTrials.gov. [(accessed on 21 February 2024)]; Available online: https://classic.clinicaltrials.gov/ct2/show/NCT04625907.
    1. Hallpike E. Creative participation for young cancer survivors: Designing a logo for the European paediatric Soft tissue sarcoma Study Group (EpSSG) Frontline and Relapse-Rhabdomyosarcoma Study (FaR-RMS); Proceedings of the 4th Global AYA Conference; London, UK. 13–15 July 2020.
    1. [(accessed on 21 February 2024)]. Available online: https://www.alicesarc.org/
    1. Ferrari A., Dileo P., Casanova M., Bertulli R., Meazza C., Gandola L., Navarria P., Collini P., Gronchi A., Olmi P., et al. Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a single institution. Cancer. 2003;98:571–580. doi: 10.1002/cncr.11550. - DOI - PubMed
    1. Sultan I., Qaddoumi I., Yaser S., Rodriguez-Galindo C., Ferrari A. Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: An analysis of 2600 patients. J. Clin. Oncol. 2009;27:3391–3397. doi: 10.1200/JCO.2008.19.7483. - DOI - PubMed

LinkOut - more resources